Spheroids Market Size, Share & Trends Analysis Report By Type, By Method, By Source, By Application (Developmental Biology, Personalized Medicine, Regenerative Medicine), By End Use, By Region And Segment Forecasts,
Published Date: May - 2025 | Publisher: MIR | No of Pages: 240 | Industry: healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2999 Download Sample Ask for Discount Request CustomizationSpheroids Market Size & Trends
The size of the global spheroids market was valued at USD 749.9 million in 2024 and is projected to expand with a CAGR of 22.7% during the forecast period from 2025 to 2035. The rise in demand for physiologically relevant 3D cell culture models in drug discovery, cancer research, and regenerative medicine fuels the industry for spheroids. Spheroids more closely mimic in vivo cell interactions, nutrient gradients, and tissue architecture than conventional 2D cultures, resulting in more prophetic data for drug efficacy and toxicity screening.
This has rendered them highly useful in oncology studies, where spheroids in tumors provide for better modeling of cancer activity and response to treatments. Additionally, better high-throughput screening technologies, expanded interest in personalized medicine, and enhanced investment in 3D cell culture platforms further drive adoption of spheroid-based systems in pharmaceutical, academic, and biotech industries.
Scientists and industries are actively working to develop spheroids that mimic sophisticated diseases like colon cancer, lung cancer, chronic kidney disease, and genetic disorders. Such specific innovation is driving increasing demand for spheroids in the scientific community, as these small 3D models hold tremendous promise for disease modeling and biological understanding. As of February 2024, ClinicalTrials.gov lists 106 active clinical trials involving spheroids, indicating their growing significance in translational research. Additionally, new technological innovations in spheroid model development further increase their applicability in pharmaceutical research, increasing precision in drug testing and disease analysis.
Report Coverage & Deliverables
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Market Concentration & Characteristics
The spheroids market exhibits a very high level of innovation due to the necessity for more biologically relevant models of research and drug development. Innovations include sophisticated scaffold-free and scaffold-based culture systems, integration with organ-on-chip technologies, and AI-driven analysis tools for 3D imaging and high-content screening. Novel techniques for producing uniform spheroids, co-culturing cell types, and enhancing viability considerably enhance their use in disease modeling and regenerative medicine.
The market has experienced a moderate degree of mergers and acquisitions, with bigger life science and biotech firms acquiring niche 3D culture companies or technology developers to enhance their 3D biology portfolios. Strategic acquisitions are focused on acquiring proprietary platforms, increasing high-throughput screening capabilities, and moving into 3D cell culture-based drug discovery. Although not yet as common as in wider biotech industries, M&A activity will increase as the demand for 3D models and personalized medicine increases.
The spheroid market is currently subject to a low-to-moderate regulatory burden, especially since most products are utilized for research and are not directly regulated as medical devices or therapeutics. But as spheroids increasingly find their way into translational and preclinical pipelines, regulatory oversight of reproducibility, data integrity, and validation is likely to intensify. Agencies such as the FDA and EMA are also promoting the use of more physiologically relevant models (e.g., spheroids) as alternatives to animal testing, which may drive regulatory integration more quickly.
There is a high trend of product growth, as firms launch new culture platforms (e.g., hanging drop, microfluidics, ULA), specific reagents, and combined imaging and automation solutions. Vendors also provide application-specific kits for oncology, hepatotoxicity, and neuroscience, among others, to increase market reach. The growth is also spurred by partnerships with academic institutions and CROs for the creation of custom spheroid models for specific research areas.
The spheroid market is experiencing consistent regional growth, with North America and Europe taking the lead in adoption because of robust R&D infrastructure and pharma investments. Asia Pacific is quickly emerging, fuelled by growing biotech activity in nations such as China, Japan, and South Korea, and government efforts to encourage innovative models of drug testing. Developing markets in Latin America and the Middle East are also starting to implement 3D culture systems, mainly via partnerships with world leaders and networks of academics.
Type Insights
The multicellular tumor spheroids (MCTS) segment accounted for a larger revenue share of 28.91% in 2024 and is expected to have the fastest growth rate over the forecast period. Unlike 2D monolayer cultures, MCTS replicate key tumor features such as hypoxic cores, nutrient gradients, and complex cell-cell interactions, making them highly valuable for cancer biology research and preclinical drug screening. Their relevance in modeling tumor progression, metastasis, and therapeutic response prompts widespread adoption in oncology-focused pharmaceutical and academic research. Moreover, the growing push toward replacing animal models with more ethical and predictive in vitro systems is accelerating the integration of MCTS into high-throughput drug development workflows.
The mammospheres segment is expected to grow significantly over the forecast period. Mammospheres replicate the 3D structure of breast tissue and closely mimic the biology of CSCs, making them invaluable for studying breast cancer progression, metastasis, and therapeutic resistance. As the demand for personalized medicine grows, mammospheres are increasingly used to test the efficacy of new treatments, including targeted therapies and immunotherapies, in preclinical models. Furthermore, their role in understanding the molecular mechanisms of CSCs drives their adoption across academic and pharmaceutical research sectors, further fueling the growth of the spheroid industry.
Method Insights
The hanging drop method segment accounted for a larger revenue share of 31.34% in 2024 and is expected to have a fastest growth rate over the forecast period. This method promotes the spontaneous aggregation of cells into spheroids by utilizing gravity, allowing for the formation of structurally intact and physiologically relevant cell clusters. As demand for high-quality, scalable, and cost-effective 3D culture systems increases, the hanging drop method has become a preferred choice in academic and industrial settings for cancer research, drug screening, and regenerative medicine. Its simplicity and versatility in producing spheroids for various applications accelerate its adoption, further fueling spheroid industry growth.
The low cell attachment plates segment is expected to grow significantly over the forecast period. These plates are specially coated to prevent cell adhesion, encouraging cells to aggregate and form spheroids naturally, which closely mimic the in vivo microenvironment. Their compatibility with automated systems and high-throughput screening makes them ideal for pharmaceutical and biotech applications, especially in cancer research and drug toxicity studies. The increasing demand for more physiologically relevant and cost-effective 3D culture tools is driving widespread adoption of low cell attachment plates, supporting the overall growth of the spheroids industry.
Source Insights
The cell line segment accounted for a larger revenue share of 56.64% in 2024. Cell lines are a major source for spheroids because they provide a standardized, reproducible, and cost-effective resource for generating 3D spheroid models across a wide range of research applications. Established cancer cell lines, stem cell lines, and primary cells are routinely used to form spheroids for studying tumor behavior, drug resistance, tissue development, and stem cell differentiation. The vast availability of disease-specific and genetically modified cell lines enables researchers to create spheroids tailored to various pathological conditions, enhancing experimental outcomes' relevance and translational value. Moreover, the compatibility of these cell lines with high-throughput 3D culture platforms further boosts their adoption in pharmaceutical R&D and academic research, propelling the market growth.
The iPSCs derived cells segment is expected to grow fastest over the forecast period. iPSCs can be differentiated into various cell types and organized into spheroids, allowing researchers to model complex biological processes, study patient-specific disease mechanisms, and evaluate drug responses in a personalized manner. This is particularly valuable for regenerative medicine, toxicology, and neurological disease research. The growing demand for predictive, human-relevant models that reduce reliance on animal testing is accelerating the adoption of iPSC-derived spheroids across pharmaceutical, biotech, and academic sectors, fueling the market expansion.
Application Insights
The developmental biology segment accounted for the largest revenue share of 30.17% in 2024. Spheroids drive significant advancements in developmental biology by providing a more realistic 3D model system to study tissue morphogenesis, cellular differentiation, and organogenesis. Unlike 2D cultures, spheroids enable observing cell behavior in a spatial context that closely mimics early embryonic development. This makes them ideal for investigating the signaling pathways and gene expression patterns involved in developmental processes. Researchers are increasingly using spheroids, such as embryoid bodies, to model early-stage tissue formation and stem cell differentiation, which is crucial for understanding congenital disorders and advancing regenerative medicine. This growing application of spheroids in developmental biology fuels demand for more refined and scalable 3D culture systems.
The regenerative medicine segment is expected to witness the highest CAGR over the forecast period. Transplantation of spheroids derived from adult stem cells helps replace diseased tissue or organs. For instance, XanoMATRIX surfaces are used to grow and cultivate mesenchymal stem cells and for regenerative medicine. Such developments boost the segment’s growth.
End Use Insights
The biotechnology and pharmaceutical industry segment held the highest revenue share of 46.33% in 2024. Spheroids provide a more physiologically accurate environment compared to conventional 2D cultures, allowing for more precise predictions of drug efficacy, toxicity, and pharmacokinetics. This translates into lower costs of drug development and fewer clinical failures at the late stages. Additionally, the increasing focus on personalized medicine and the demand for disease-specific models have rendered spheroids indispensable tools in oncology, neurology, and regenerative medicine research. Pharmaceutical firms also invest in high-throughput screening platforms that are compatible with spheroid models, further driving their adoption into mainstream R&D pipelines.
The academic & research institutes segment is anticipated to experience the highest CAGR during the forecast period. Spheroids allow researchers to replicate 3D cellular microenvironments, providing more valid information on tumor biology, stem cell differentiation, and tissue development than traditional 2D models. With higher government agency funding and collaborative grants, institutions are using spheroid models for exploratory research, translational studies, and drug screening purposes. Additionally, the increasing interdisciplinary research using bioengineering, materials science, and cell biology is further enhancing the use of spheroids in educational institutions.
Regional Insights
North America had the highest revenue market share of 36.12% in 2024. This is largely due to the improvements in technology that have allowed for the creation of 3D spheroids. These new models are superior to the conventional 2D cell culture platforms because they are more representative of human tissue architecture. By establishing a microenvironment that closely approximates in vivo conditions, scientists are able to receive more valid and predictive results from their experiments.
U.S. Spheroids Market Trends
The U.S. market for spheroids is witnessing tremendous growth owing to the presence of market leaders, like Corning and Thermo Fisher Scientific, Inc., in the local market. Additionally, global funding agencies present in this region are also expected to fuel demand for spheroid culture systems.
Europe Spheroids Market Trends
The market for spheroids in Europe is expected to grow vastly over the forecast period owing to several factors. One of the principal growth drivers is the expanding need for personalized medicine, which has accentuated the need for patient-specific models of drug discovery and development very strongly. Spheroids offer the opportunity to create such models since they can mimic human tissue structure in a 3D model. Such technology can potentially reduce the time and cost associated with traditional drug discovery methods and improve their effectiveness and safety.
The UK spheroids market is growing at a tremendous rate due to technological advancements. The UK government has invested immensely in genomics research, leading to the development of new technologies for the manufacture of spheroids. For instance, in May 2023, Jeremy Hunt, the Chancellor, revealed a USD 700.65 million war chest to build the UK life sciences sector, which is expected to positively impact the market. The funds will be utilized in research and development in various areas of life sciences, including genomics, artificial intelligence (AI), and cell and gene therapies. The financing will also be utilized to support financing a new National Institute for Health Protection (NIHP), which will advance public health by building novel treatments and vaccines. These developments are likely to generate demand for spheroids, considering how well they are suited for preclinical assessment of novel treatments and vaccines.
The French market for spheroids is expanding with the French government heavily investing in stem cell technology. Stem cells can be differentiated into various cell types and are utilized to form spheroids that mimic human tissue structures in the laboratory. There are several institutes and programs run by the French government for conducting stem cell research, such as the Institut Clinique de la Souris (ICS) and the Centre de Recherche en Cancérologie de Marseille (CRCM). These institutes have assisted in the development of stem cell technology and facilitated research on spheroids for a wide range of applications like drug discovery, disease modeling, and regenerative medicine.
Germany spheroids market is being aggressively funded by its government through funding schemes in research and development. For instance, the German Research Foundation (DFG) provides grants for research studies in spheroids, like disease modeling studies, drug discovery studies, and regenerative medicine studies. Moreover, the government of Germany has established various research institutions and programs focused on spheroids, such as the Fraunhofer Institute for Cell Therapy and Immunology (IZI) and the German Center for Neurodegenerative Diseases (DZNE). These institutions are where scientists can visit and collaborate and make headway in the field of spheroids.
Asia Pacific Spheroids Market Trends
The Asia Pacific spheroids market is anticipated to exhibit the highest growth during the forecast period as a result of continuous advancements in stem cell research. An increase in alliances between the major market players is anticipated to increase the market growth. For example, in March 2020, UPM Biomedicals and Nichirei Biosciences entered a partnership agreement to distribute UPM culture products in Japan. This increased the availability of natural hydrogels for spheroid culture.
China spheroids market has experienced tremendous growth in 3D cell culture technology, particularly with respect to spheroids. Consequently, China's market for such advanced cell culture models is growing. China's technology of 3D cell culture has recently improved with collaborations that advance research in the field. For example, in October 2020, Merck partnered with D1Med to promote the development of three-dimensional (3D) cell culture technology in China, with Merck supplying 3D cell culture products and technical expertise. This partnership indicates the growing interest in 3D cell culture methods, which are becoming increasingly popular in cell biology and have potential for different applications, such as tissue engineering, regenerative medicine, drug discovery, toxicity testing, and spheroid formation.
Japan's strong emphasis on precision medicine, regenerative therapies, and cancer research is the key driver for the spheroids market. Government policies like the Japan Regenerative Medicine Act and investments from agencies like AMED (Japan Agency for Medical Research and Development) have acted as catalysts to promote the use of cutting-edge 3D cell culture technologies, such as spheroids. Japanese academic and pharmaceutical research organizations are increasingly adopting tumor spheroids for toxicology testing, drug screening, and modeling diseases because they are able to model in vivo conditions more effectively than 2D cultures. Also, Japan's increasing population with age and the subsequent increase in chronic diseases are creating more demand for more predictive preclinical models, further driving the regional spheroid market growth.
Middle East And Africa Spheroids Market Trends
The MEA spheroid market is fueled by an expanding emphasis on improving healthcare infrastructure, expanding investment in biomedical research, and growing government efforts to enhance precision medicine and biotech. Life sciences are given priority by nations like the United Arab Emirates and Saudi Arabia in their economic diversification initiatives, which has led to the development of research centers as well as partnerships with international biotech companies. The increasing burden of chronic diseases, such as cancer and diabetes, in the region is also driving demand for more predictive and patient-relevant 3D cell models such as spheroids.
Saudi Arabia spheroids market is growing rapidly because the Saudi Arabian government is investing heavily in research and development across all sectors, including healthcare. For example, the hefty investment in healthcare infrastructure as part of Saudi Arabia's Vision 2030 program is likely to significantly increase the market in the country. Such investments worth USD 65 billion are promoting the creation of new technologies, products, and services in the healthcare sector, such as spheroids, and are resulting in their commercialization in the Saudi Arabian market.
Key Spheroids Company Insights
Competition between the current players has grown due to advancements in technology and its possible uses in the field of drug discovery. Thus, major players are constantly engaged in the introduction of new, better products. For example, Perkin Elmer provides a broad range of platforms for detecting, handling, and analyzing spheroids. Researchers have produced mini lungs for research purposes in order to find out about the mechanism of SARS-CoV-2 entry and propagation within tissues. Organoids have been used for exploring the protection mechanism of the tissues against SARS-CoV-2 as well. It is likely that it can facilitate development of a vaccine for curing.
Regulatory compliances as well as ethics govern the competition profoundly. Those companies that successfully navigate tight approval channels and create standard, scalable spheroid models will own the market. As precision medicine demand increases, companies investing in personalized spheroid platforms will gain substantial market share. The competition is further compounded with new startups launching cost-efficient, high-throughput spheroid solutions, threatening incumbents. With ongoing advancements and growing regulatory backing, the market for spheroids is expected to have sustained growth, fueled by new prospects in the biotech, pharma, and healthcare industries.
The preceding analysis points to the competitive landscape of the firms, with larger companies having a stronger global presence and strategic activity. The firms such as Merck KGaA, Lonza, and Thermo Fisher Scientific Inc. exhibit strong presence in all three groups, indicating a balanced market presence. Corning Inc. exhibits moderate strength, specifically in strategic efforts and geographic presence.
Key Spheroids Companies
The following are the leading companies in the spheroids market. These companies collectively hold the largest market share and dictate industry trends.
- Thermo Fisher Scientific Inc.
- Corning Incorporated
- Merck KGaA
- Lonza Group AG
- InSphero AG
- Greiner Bio-One International GmbH
- 3D Biotek LLC
- CN Bio Innovations
- Kuraray Co., Ltd.
- Tecan Group Ltd.
Recent Developments
-
In June 2023, Inventia Life Science partnered with Biotron Healthcare to distribute its RASTRUM miniaturized 3D cell culturing platform in India. This collaboration is expected to benefit the field of organoids and spheroids by making the advanced technology of the RASTRUM platform more accessible to researchers in India.
-
In April 2023, InSphero AG, a leading innovator in 3D cell-based assay technology, expanded its reach into the Indian market by partnering with Bionova Supplies. Through this agreement, InSphero’s patented Akura 96 and 384 Spheroid Microplates will now be accessible to researchers across the country.
-
In January 2023, ReLive Biotechnologies announced that its SpheChon 10-70 spheroids/cm² has received NDA approval from the Health Sciences Authority (HSA) in Singapore. This represents a significant milestone in the company’s global expansion efforts.
Spheroids Market Report Scopes
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 0.89 billion |
|
Revenue forecast in 2030 |
USD 2.46 billion |
|
Growth rate |
CAGR of 22.7% from 2025 to 2035 |
|
Actual data |
2018 - 2024 |
|
Forecast period |
2025 - 2035 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2035 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Type, method, source, application, end use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico, UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Thermo Fisher Scientific Inc.; Corning Incorporated; Merck KGaA; Lonza Group AG; InSphero AG; Greiner Bio-One International GmbH; 3D Biotek LLC; CN Bio Innovations; Kuraray Co., Ltd.; Tecan Group Ltd. |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Spheroids Market Report Segmentation
Type Outlook (Revenue, USD Million, 2018 - 2035)
-
-
Multicellular tumor spheroids (MCTS)
-
Neurospheres
-
Mammospheres
-
Hepatospheres
-
Embryoid bodies
-
-
Method Outlook (Revenue, USD Million, 2018 - 2035)
-
Micropatterned Plates
-
Low Cell Attachment Plates
-
Hanging Drop Method
-
Others
-
-
Source Outlook (Revenue, USD Million, 2018 - 2035)
-
Cell Line
-
Primary Cell
-
iPSCs Derived Cells
-
-
Application Outlook (Revenue, USD Million, 2018 - 2035)
-
Developmental Biology
-
Personalized Medicine
-
Regenerative Medicine
-
Disease Pathology Studies
-
Drug Toxicity & Efficacy Testing
-
-
End Use Outlook (Revenue, USD Million, 2018 - 2035)
-
Biotechnology and Pharmaceutical industries
-
Academic & Research Institutes
-
Hospitals and Diagnostic centers
-
-
Regional Outlook (Revenue in USD Million, 2018 - 2035)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Sweden
-
Norway
-
Denmark
-
-
Asia Pacific
-
China
-
Japan
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa
-
Saudi Arabia
-
South Africa
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy